文献速递神经肌肉病

阿米吡啶在重症肌无力中的疗效与安全性:随机双盲安慰剂对照交叉试验

Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.
PubMed 文献 · Neurology · 2026-04-07

该随机双盲安慰剂对照交叉试验纳入20例吡啶斯的明控制不佳的AChR抗体阳性重症肌无力患者,评估阿米吡啶添加治疗的疗效与安全性。结果显示,阿米吡啶30mg和60mg与安慰剂相比MGII评分差异均无统计学意义,且不良事件更常见。

要点

  • 在AChR抗体阳性重症肌无力患者中,阿米吡啶添加治疗未优于单用吡啶斯的明。
  • 阿米吡啶30mg和60mg组不良事件发生率分别为60%和75%,高于安慰剂组的30%。
  • 常见不良事件包括感觉异常、疲劳、麻木、头晕和睡眠障碍。

核心结论

  • 在AChR抗体阳性重症肌无力患者中,阿米吡啶添加至吡啶斯的明治疗未优于单用吡啶斯的明,且不良事件发生率更高。

研究设计与样本

  • 随机、双盲、安慰剂对照交叉试验,在荷兰莱顿大学医学中心进行,纳入20例MGII评分>10的AChR抗体阳性重症肌无力患者。
  • 患者按1:1:1随机分配至3种治疗序列,每个治疗期5天,期间分别接受阿米吡啶缓释片30mg、60mg或安慰剂,治疗间洗脱2天。

主要发现

  • MGII评分估计平均差异:阿米吡啶30mg vs 安慰剂为-1.0(95% CI -4.1至2.0,p=0.681)。
  • MGII评分估计平均差异:阿米吡啶60mg vs 安慰剂为-1.7(95% CI -4.7至1.4,p=0.379)。
  • 药代动力学参数与MGII之间无统计学显著关联。
  • 未报告严重不良事件;不良事件在阿米吡啶30mg组(12例[60%])和60mg组(15例[75%])比安慰剂组(6例[30%])更常见。
  • 最常见不良事件为感觉异常、疲劳、麻木、头晕和睡眠障碍;3例患者因不良事件提前停用阿米吡啶。

关键数值与推荐

  • 主要结局为阿米吡啶两种剂量与安慰剂之间MGII评分的差异。
  • 阿米吡啶30mg与安慰剂比较:估计平均差异-1.0(95% CI -4.1至2.0,p=0.681)。
  • 阿米吡啶60mg与安慰剂比较:估计平均差异-1.7(95% CI -4.7至1.4,p=0.379)。

临床怎么用

  • 对于吡啶斯的明控制不佳的AChR抗体阳性重症肌无力患者,添加阿米吡啶缺乏疗效证据且不良事件增加,不应常规使用。

局限性

  • 样本量较小(20例),可能影响统计效能和结果的普遍性。
  • 每个治疗期仅5天,无法评估长期疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Amifampridine, a short-acting potassium-channel blocker, is the first-line treatment for Lambert-Eaton myasthenic syndrome. Its benefit as add-on to pyridostigmine in acetylcholine receptor (AChR)-positive myasthenia gravis (MG) has been proposed, but no randomized controlled trials have been conducted. We aimed to evaluate the efficacy and safety of amifampridine in AChR-MG with insufficient symptom control on pyridostigmine. METHODS: A randomized, double-blind, placebo-controlled crossover trial was conducted at Leiden University Medical Center, a tertiary center for the treatment of MG in the Netherlands, as part 2 of the IMPACT-MG trial. Eligible patients had either completed part 1 (pyridostigmine vs placebo) or failed the initial 2-day pyridostigmine washout, and had an Myasthenia Gravis Impairment Index (MGII) score >10. Participants were randomized (1:1:1) to 1 of 3 treatment sequences. Each treatment period lasted 5 days, with a 2-day washout between treatments, during which participants received either 30 mg or 60 mg of amifampridine modified release, or placebo. The primary outcome was the difference in MGII score between the 2 amifampridine dosages and placebo. Pharmacokinetics, safety, and tolerability were assessed throughout the trial. RESULTS: Between March 2023 and April 2024, 20 patients were enrolled (median age 60 years, 55% female). For the MGII score, the estimated mean differences were -1.0 (95% CI -4.1 to 2.0, p = 0.681) for amifampridine 30 mg vs placebo and -1.7 (95% CI -4.7 to 1.4, p = 0.379) for amifampridine 60 mg vs placebo. No statistically significant association was observed between pharmacokinetic parameters and the MGII. No serious adverse events were reported. Adverse events were more common with amifampridine 30 mg (12 patients [60%]) and 60 mg (15 patients [75%]), compared with placebo (6 patients [30%]), with paresthesia, fatigue, numbness, dizziness, and sleep disturbances most frequently reported. Three patients discontinued amifampridine early due to adverse events. DISCUSSION: The addition of amifampridine to pyridostigmine was not superior to treatment with pyridostigmine alone and was associated with a higher incidence of adverse events. TRIAL REGISTRATION INFORMATION: The trial was registered at EudraCT (2021-004110-20, registration date: July 12, 2022) and ClinicalTrials.gov (NCT05919407, registration date: June 16, 2023). First patient enrolled: March 23, 2023. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in patients with AChRAb+ MG, the addition of amifampridine to pyridostigmine was not superior to treatment with pyridostigmine alone and was associated with a higher incidence of adverse events.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Remijn-Nelissen L, Bakker WR, van Gelder T, et al. Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial. Neurology. 2026. PMID: 41945880. doi:10.1212/WNL.0000000000214715

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。